Efficient identification of a novel cancer/testis antigen for immunotherapy using three-step microarray analysis

Takeshi Yokoe, Fumiaki Tanaka, Koshi Mimori, Hiroshi Inoue, Takahiro Ohmachi, Masato Kusunoki, Masaki Mori

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Advanced technology in molecular biology has provided us powerful tools for the diagnosis and treatment for cancer. We herein adopted a new methodology to identify a novel cancer/ testis (CT) antigen with high frequency of expression in colorectal cancer as follows: (a) combining laser microdissection and cDNA microarray was used to analyze the gene expression profile of colorectal cancer cells; (b) genes overexpressed in testis and underexpressed in normal colon epithelium were analyzed using cDNA microarray; and (c) the gene expression profile of colorectal cancer cells was compared with that of normal testis. Using this methodology, we selected 38 candidates for CT antigen. Among these genes, we identified a novel CT antigen, serine/threonine kinase 31 (STK31), which was previously reported as a gene expressed in spermatogonia. Reverse transcription-PCR analysis showed that STK31 gene expression levels in cancer samples were significantly higher (P < 0.0001) than those in normal samples. The STK31 gene was frequently expressed not only in colorectal cancer but also in gastric and esophageal cancer. Moreover, STK31 peptide was able to elicit specific CTLs and induced CTLs lysed either peptide-loading or endogenously STK31-expressing target cells. These results showed that the new methodology in this study facilitated identification of CT antigens and that STK31 may be a candidate for cancer immunotherapy against gastrointestinal cancer.

Original languageEnglish
Pages (from-to)1074-1082
Number of pages9
JournalCancer Research
Volume68
Issue number4
DOIs
Publication statusPublished - Feb 15 2008

Fingerprint

Protein-Serine-Threonine Kinases
Testicular Neoplasms
Microarray Analysis
Immunotherapy
Antigens
Colorectal Neoplasms
Oligonucleotide Array Sequence Analysis
Transcriptome
Genes
Testis
Neoplasms
Microdissection
Spermatogonia
Peptides
Gastrointestinal Neoplasms
Esophageal Neoplasms
Reverse Transcription
Stomach Neoplasms
Molecular Biology
Colon

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Efficient identification of a novel cancer/testis antigen for immunotherapy using three-step microarray analysis. / Yokoe, Takeshi; Tanaka, Fumiaki; Mimori, Koshi; Inoue, Hiroshi; Ohmachi, Takahiro; Kusunoki, Masato; Mori, Masaki.

In: Cancer Research, Vol. 68, No. 4, 15.02.2008, p. 1074-1082.

Research output: Contribution to journalArticle

Yokoe, Takeshi ; Tanaka, Fumiaki ; Mimori, Koshi ; Inoue, Hiroshi ; Ohmachi, Takahiro ; Kusunoki, Masato ; Mori, Masaki. / Efficient identification of a novel cancer/testis antigen for immunotherapy using three-step microarray analysis. In: Cancer Research. 2008 ; Vol. 68, No. 4. pp. 1074-1082.
@article{4320337993e7458aafef6acea023f086,
title = "Efficient identification of a novel cancer/testis antigen for immunotherapy using three-step microarray analysis",
abstract = "Advanced technology in molecular biology has provided us powerful tools for the diagnosis and treatment for cancer. We herein adopted a new methodology to identify a novel cancer/ testis (CT) antigen with high frequency of expression in colorectal cancer as follows: (a) combining laser microdissection and cDNA microarray was used to analyze the gene expression profile of colorectal cancer cells; (b) genes overexpressed in testis and underexpressed in normal colon epithelium were analyzed using cDNA microarray; and (c) the gene expression profile of colorectal cancer cells was compared with that of normal testis. Using this methodology, we selected 38 candidates for CT antigen. Among these genes, we identified a novel CT antigen, serine/threonine kinase 31 (STK31), which was previously reported as a gene expressed in spermatogonia. Reverse transcription-PCR analysis showed that STK31 gene expression levels in cancer samples were significantly higher (P < 0.0001) than those in normal samples. The STK31 gene was frequently expressed not only in colorectal cancer but also in gastric and esophageal cancer. Moreover, STK31 peptide was able to elicit specific CTLs and induced CTLs lysed either peptide-loading or endogenously STK31-expressing target cells. These results showed that the new methodology in this study facilitated identification of CT antigens and that STK31 may be a candidate for cancer immunotherapy against gastrointestinal cancer.",
author = "Takeshi Yokoe and Fumiaki Tanaka and Koshi Mimori and Hiroshi Inoue and Takahiro Ohmachi and Masato Kusunoki and Masaki Mori",
year = "2008",
month = "2",
day = "15",
doi = "10.1158/0008-5472.CAN-07-0964",
language = "English",
volume = "68",
pages = "1074--1082",
journal = "Cancer Research",
issn = "0008-5472",
number = "4",

}

TY - JOUR

T1 - Efficient identification of a novel cancer/testis antigen for immunotherapy using three-step microarray analysis

AU - Yokoe, Takeshi

AU - Tanaka, Fumiaki

AU - Mimori, Koshi

AU - Inoue, Hiroshi

AU - Ohmachi, Takahiro

AU - Kusunoki, Masato

AU - Mori, Masaki

PY - 2008/2/15

Y1 - 2008/2/15

N2 - Advanced technology in molecular biology has provided us powerful tools for the diagnosis and treatment for cancer. We herein adopted a new methodology to identify a novel cancer/ testis (CT) antigen with high frequency of expression in colorectal cancer as follows: (a) combining laser microdissection and cDNA microarray was used to analyze the gene expression profile of colorectal cancer cells; (b) genes overexpressed in testis and underexpressed in normal colon epithelium were analyzed using cDNA microarray; and (c) the gene expression profile of colorectal cancer cells was compared with that of normal testis. Using this methodology, we selected 38 candidates for CT antigen. Among these genes, we identified a novel CT antigen, serine/threonine kinase 31 (STK31), which was previously reported as a gene expressed in spermatogonia. Reverse transcription-PCR analysis showed that STK31 gene expression levels in cancer samples were significantly higher (P < 0.0001) than those in normal samples. The STK31 gene was frequently expressed not only in colorectal cancer but also in gastric and esophageal cancer. Moreover, STK31 peptide was able to elicit specific CTLs and induced CTLs lysed either peptide-loading or endogenously STK31-expressing target cells. These results showed that the new methodology in this study facilitated identification of CT antigens and that STK31 may be a candidate for cancer immunotherapy against gastrointestinal cancer.

AB - Advanced technology in molecular biology has provided us powerful tools for the diagnosis and treatment for cancer. We herein adopted a new methodology to identify a novel cancer/ testis (CT) antigen with high frequency of expression in colorectal cancer as follows: (a) combining laser microdissection and cDNA microarray was used to analyze the gene expression profile of colorectal cancer cells; (b) genes overexpressed in testis and underexpressed in normal colon epithelium were analyzed using cDNA microarray; and (c) the gene expression profile of colorectal cancer cells was compared with that of normal testis. Using this methodology, we selected 38 candidates for CT antigen. Among these genes, we identified a novel CT antigen, serine/threonine kinase 31 (STK31), which was previously reported as a gene expressed in spermatogonia. Reverse transcription-PCR analysis showed that STK31 gene expression levels in cancer samples were significantly higher (P < 0.0001) than those in normal samples. The STK31 gene was frequently expressed not only in colorectal cancer but also in gastric and esophageal cancer. Moreover, STK31 peptide was able to elicit specific CTLs and induced CTLs lysed either peptide-loading or endogenously STK31-expressing target cells. These results showed that the new methodology in this study facilitated identification of CT antigens and that STK31 may be a candidate for cancer immunotherapy against gastrointestinal cancer.

UR - http://www.scopus.com/inward/record.url?scp=39449110979&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=39449110979&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-07-0964

DO - 10.1158/0008-5472.CAN-07-0964

M3 - Article

C2 - 18281482

AN - SCOPUS:39449110979

VL - 68

SP - 1074

EP - 1082

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 4

ER -